Taranabant is a synthetic compound that belongs to the class of selective cannabinoid receptor antagonists. It was primarily developed for potential therapeutic applications in the treatment of obesity and related metabolic disorders. The substance acts on the cannabinoid receptors in the brain, particularly the CB1 receptor, which is involved in appetite regulation and energy balance. Taranabant has been studied for its ability to reduce food intake and promote weight loss by blocking the effects of endocannabinoids that stimulate appetite. Its chemical structure features a unique arrangement of functional groups that contribute to its biological activity. However, clinical trials have shown mixed results regarding its efficacy and safety, leading to concerns about side effects such as anxiety and depression. As a result, further development of Taranabant has been limited, and it has not been approved for clinical use. Overall, while Taranabant presents interesting pharmacological properties, its clinical viability remains uncertain due to safety and tolerability issues.

Taranabant

701977-09-5: Mk 0364, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]propanamide, Propanamide, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]-, Taranabant

Inverse agonist of cannabinoid receptor CB1R. Taranabant was studied for its effect on smoking cessation and inducing weight loss. Serious adverse effects associated with this compound prevented further development as a drug in the clinic.

Taranabant: potent CB1 receptor inverse agonist; inhibits agonists with 0.13 nM Ki in vitro.

CAS 701977-09-5: Taranabant

Taranabant

Ref: 3D-FT103970

Taranabant

Ref: TM-T13080L